Eesti Teadusinfosüsteem

Antud projekti eesmärgiks on töötatada välja prognostiline süsteemimeditsiiniline mudel atoopilise dermatiidi ja psoriaasi kliiniliste ja molekulaarsete andmete põhjal. Täpsemateks eesmärkideks on (i) identifitseerida kliiniliselt relevantsed funktsionaalsed biomarkerid, (ii) paranada meie teadmisi nende haiguste molekulaarsetest mehhanismidest ning omavahelistest sarnasustest ja erinevustest, (iii) viia funktsionaalsed biomarkerid, mis võimldavad identifitseerida patsientide rühmi ja prognoosida vastust erinevatele ravimitele ravimarendusse ja kliinilisse praktikasse. Oma eesmärkide täitmiseks loob BIOMAP tsentraalse, multidimensionaalse ja avatud andmebaasi, mis sisaldab kliinilisi, naha ja vere rakkude põhiseid molekulaarseid ning keskkonna andmeid. Parimad funktsionaalsed biomarkerite kandidaadid on plaanis viia kliinilisse rakendusse. Projekti kaugem eesmärk on muuta ravi personaalsemaks, efektiivsemaks, kiirendada ravimiarenduse tsüklit, vähendada nende haiguste mõju ja parandad ravi tulemusi.

Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.